Lanean...
Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?
A small proportion of patients with advanced hepatocellular carcinoma harbor FGF3/4 gene amplifications in an 11q13 amplicon. A recent report suggests that the presence of this alteration might enrich for sensitivity to sorafenib. Further, there is growing evidence that interference with the FGF/FGF...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
AME Publishing Company
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4141298/ https://ncbi.nlm.nih.gov/pubmed/25202691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2304-3881.2014.07.03 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|